Article Text

PDF

Methothrexate directly inhibits RANKL expression and osteoclast formation in very early arthritis
  1. S Revu,
  2. P Neregård,
  3. E af Klint,
  4. A I Catrina
  1. Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden

Statistics from Altmetric.com

Objective

Methotrexate (MTX) is one of the most widely used therapies in rheumatoid arthritis (RA) due to its anti-inflammatory and potential bone protection effect. Bone biology is governed by the RANKL/RANK/OPG system that determines the balance between bone formation by osteoblasts and bone resorption by osteoclasts. We investigated the effects of MTX on the RANKL/RANK/OPG system in vivo and in vitro.

Methods

16 patients with newly diagnosed RA (mean disease duration 1 week) were started on MTX 10 mg once a week and increased by 10 mg each week until a stable dose of 20 mg once a week was reached. Patients were naïve for other disease-modifying antirheumatic drugs and allowed to take prednisolone to a maximum dose of 10 mg daily and non-steroidal inflammatory drugs as clinically indicated. Synovial biopsies were obtained by needle arthroscopy at baseline and 8 weeks after initiation of therapy. x-rays of hands and feet were obtained at baseline and 1 year after diagnosis. Immunohistochemical analysis was performed to detect RANKL, RANK and OPG in the synovial biopsies. We further investigated the in vitro effect of MTX on synovial fluid-derived mononuclear cells, synovial fluid mononuclear cells (SFMC) (by immunohistochemistry), osteoblasts (by real-time PCR and western blot analysis) and osteoclast formation (tartrate-resistant acid phosphatase (TRAP) staining). Statistical analysis was performed using the Wilcoxon and Mann-Whitney test when appropriate.

Results

Nine patients (56%) were responders to therapy according to EULAR criteria. Two patients had erosions at inclusion in the study and five more developed erosions at 1-year follow-up in both the responder and non-responder groups. MTX treatment decreased synovial inflammation with a significant reduction of synovial cellularity. In parallel, MTX decreased synovial RANK expression and the RANKL/OPG ratio, mainly in the subgroup of RA patients with no radiological progression at 1-year follow-up. We confirmed the effect on RANK expression in SFMC cultured in vitro with MTX. A decrease in the RANKL/OPG ratio was also observed in cultured osteoblasts at both the mRNA and protein levels. MTX blocks osteoclastogenesis from PBMC despite the presence of macrophage colony stimulating factor and RANKL, indicating that MTX directly inhibits osteoclastogenesis.

Conclusions

MTX directly affects the RANKL/RANK/OPG system and inhibits osteoclasts formation providing an attractive explanation for the bone-sparing effect of MTX.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.